9
Active INDs
4
Technology Platforms
600
Employees

Recent News

Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update

Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update

Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors

Athenex, Inc. to Report Second Quarter 2020 Earnings Results on August 6, 2020

Athenex Appoints Teresa Bair, Esq. as Executive Officer and General Counsel

Athenex Announces $225 Million Loan Agreement with Oaktree

Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer

Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program

Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.
At the 2019 San Antonio Breast Cancer Symposium, Athenex Oncology raised awareness of chemotherapy induced peripheral neuropathy. Visitors performed everyday tasks, while wearing experiential neuropathy gloves.
Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.